In vivo Magnetic Resonance Imaging (MRI) of experimental tumour models provides effective means of monitoring brain tumour growth, as well as the effects of different antiblastic agents, while Magnetic Resonance Spectroscopy (MRS) represents a useful method to observe biochemical characterisation and peculiar metabolic alterations correlated with tumour growth and progression or induced by pharmacological treatments. In our previous experience, the most relevant 1H-MRS parameter obtained by analysing bioptic specimens derived from human brain gliomas was the ratio R between the Choline peak (a composite resonance band) and the total Creatine signal, which was correlated with tumour malignancy grading. In the present study, we analysed experimental brain tumours obtained in Wistar male rats by stereotactic inoculation of C6 glioma cells. Measurements were carried out in vivo on a SISCO MRI/MRS system (4.7 T) and in vitro by a Bruker spectrometer (9.4 T). In animals treated with multiple doses of BCNU, volumetric measurements by MRI showed a significant delay in tumour growth. In vitro analyses on tumour extracts showed that the R value increased during tumour growth and with malignant progression. Analyses performed 24 hours after the treatment with a single i.p. dose of BCNU showed modifications in the level of some peculiar metabolites. These preliminary results justify the interest of extending MRS analysis to preclinical non-invasive investigation of novel antiblastic drugs. New unconventional agents, evaluated with different MRS approaches, are presently under study.
|Number of pages||1|
|Journal||Italian Journal of Neurological Sciences|
|Publication status||Published - 1997|
ASJC Scopus subject areas
- Clinical Neurology